secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K/A
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001104659-23-099708
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood files audited VectivBio financials: 2022 net loss $94M, 2021 & 2022 restated
--------------------------------------------------------------------------------

- VectivBio 2022 revenue $27.3M from Asahi Kasei partner deal; net loss $94.1M.
- VectivBio held $221.4M cash at Dec 31, 2022; total assets $252.6M.
- Restated 2021 and 2022 statements to correct a misstatement; no further details here.
- Pro forma combined results for Ironwood + VectivBio for H1 2023 and FY2022 included in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923099708/0001104659-23-099708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923099708/tm2325734d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-099708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer